Curated News
By: NewsRamp Editorial Staff
April 25, 2025
Calidi Biotherapeutics Announces Inducement Grant to New CEO Dr. Eric Poma
TLDR
- New CEO of Calidi Biotherapeutics granted 726,412 stock options at $0.469, enhancing leadership advantage.
- Calidi Biotherapeutics approved non-qualified stock option grant for CEO Poma, with vesting details explained.
- Calidi Biotherapeutics' innovative technology empowers the immune system to combat cancer, potentially improving patient outcomes.
- Calidi Biotherapeutics' approach of using stem cell-based platforms carrying oncolytic viruses for cancer treatment is cutting-edge.
Impact - Why it Matters
This news matters as it highlights the appointment of a new CEO at Calidi Biotherapeutics and the company's innovative approach to developing targeted antitumor virotherapies. The grant signifies confidence in Dr. Poma's leadership and the potential for Calidi's technology to revolutionize cancer treatment, offering hope for improved efficacy and patient safety in oncology.
Summary
Calidi Biotherapeutics (NYSE American: CLDI) announced the approval of an inducement non-qualified stock option grant to new CEO Eric Poma, Ph.D. The grant includes the option to purchase 726,412 shares at an exercise price of $0.469. The options will vest over four years, in accordance with Section 711 of the NYSE American LLC Company Guide.
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. Their stem cell-based platforms utilize potent allogeneic stem cells carrying oncolytic viruses for multiple oncology indications. The company's off-the-shelf enveloped virotherapies are designed to target solid tumors, potentially treating metastatic disease.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Calidi Biotherapeutics Announces Inducement Grant to New CEO Dr. Eric Poma
